Login
IRulya Therapeutics Inc. logo

IRulya Therapeutics Inc.

quincetx.com

What Do They Do?

Develops a drug-delivery platform that encapsulates medicines in patients’ own red blood cells for potential rare-disease treatments.

How Are They Changing?

Since the FY2025 annual report
  • Oct 7, 2026 Relaunched around LAM-001 after Orphai merger It changed its name, shifted focus to LAM-001 and appointed Brigette Roberts as CEO.
  • Sep 8, 2026 Sold AIDE and eDSP assets to Ayma Ayma paid $450,000 for the former subsidiary, related intellectual property and machines.

Drug-development focus The older report centered on a bone-targeting drug platform for fractures and skeletal disease; the latest describes a platform that encapsulates drugs in patients’ own red blood cells for rare-disease treatment.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support